Potency and Durability of Antiretroviral Therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue SUPPL. 2, 2003, Pages

  Daar, Eric S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; OUTPATIENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; VIRAL LOAD;

EID: 0242331231     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200310012-00003     Document Type: Review

References (25)

1. Whitman S, Murphy J, Cohen M, et al. Marked declines in human immunodeficiency virus-related mortality in Chicago in women, African Americans, Hispanics, young adults, and injection drug users, from 1995 through 1997. Arch Intern Med 2000;160:365-9.
2. Centers for Disease Control (CDC) and Prevention. CDC, HIV/AIDS Surveillance Report. U.S. HIV and AIDS cases reported through December 2001. September 25, 2002;13:1-44. Year-end issue.
3. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002;288:222-35.
4. Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2003; http://AIDSinfo.nih.gov.
5. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
6. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002;360:119-29.
7. 3. AIDS 2002;16:1371-81.
8. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV infected persons in different CD4-cell strata. Ann Intern Med 2003;138:620-6.
9. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286:2568-77.
10. 3: disease progression, treatment durability, and drug toxicity. Clin Infect Dis 2003;36:812-5.
11. Wood E, Hogg RS, Yip B, et al. The impact of baseline plasma HIV RNA and adherence on response to therapy and mortality after the initiation of HAART [abstract 182]. Presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 10-14, 2003.
12. Lichtenstein KA, Delaney KM, Armon C, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003;32:48-56.
13. Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1-infected adults. AIDS 2001;15:1369-77.
14. Robbins G, Shafer R, Smeaton L, et al. Antiretroviral strategies in naïve HIV+ subjects: comparison of sequential 3-drug regimens (ACTG 384) [abstract LbOr20A]. Presented at the XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002.
15. Shafer R, Robbins G, Smeaton L, et al. Antiretroviral strategies in naïve HIV+ subjects: comparison of 4-drug versus sequential 3-drug regimens (ACTG 384) [abstract LbOr20B]. Presented at the XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002.
16. van Leth F, Hassink E, Phanuphak P, et al. Results of the 2NN study: a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine [abstract 176]. Presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 10-14, 2003.
17. Hammer SM, Cooper D, Johnson M, et al. CNAAB3005 International Study Team. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA. 2001;285(9):1155-63.
18. Vibhagool A, for the CNA3014 International Study Team. Abacavir/combivir vs indinavir/combivir in therapy naive adults (CNA3014): 48-week efficacy, safety and adherence results from an open-label randomized equivalence study [abstract 063]. Presented at the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina; 2001.
19. nd International AIDS Society Conference on Pathogenesis and Treatment, Paris, France, 2003.
20. Staszewski S, Gallant J, Pozniak AL, et al. Efficacy and safety of tenofovir disoproxil fumarate (TDF) versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavirenz in HIV-1-infected patients naïve to antiretroviral therapy: 48-week interim results of study GS-99-903 [abstract LbOr17]. Presented at the XIV International AIDS Conference, July 7-12, 2002. Barcelona.
21. Staszewski S, Gallant JE, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs. stavudine when used in combination with lamivudine and efavirenz in antiretroviral naïve patients: 96-week preliminary interim results [abstract 564b]. Presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 10-14, 2003.
22. Gulick RM, Mellors JW, Havlir D, et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med 2000;133:35-9.
23. Tashima K, Staszewski S, Morales-Ramirez J, et al. 3-year durability of response with an efavirenz-containing regimen: 144-week follow-up of study 006 [abstract 224]. Presented at the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, July 2001.
24. Murphy R, Brun S, King M, et al. Lopinavir/ritonavir (Kaletra) in antiretroviral naïve HIV+ patients: 4-year follow-up [abstract H-165]. Presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 27-30, 2002.
25. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002;346:2039-46.